Ju · Brain : a journal of neurology 2017 · sham-controlled crossover trial · n=17

Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.

Cited 604 times in the scientific literature.

Level 2 - randomized trial

Sham-controlled crossover experimental study in humans

PubMed 28899014 · doi:10.1093/brain/awx148 · record verified 2026-08-31

What was done

Seventeen healthy adults aged 35–65 years without sleep disorders completed 5–14 days of home actigraphy followed by in-lab polysomnography with slow wave activity disruption. Cerebrospinal fluid was collected the following morning to measure amyloid-β, tau, total protein, YKL-40, and hypocretin. Outcomes were compared to an identical protocol with a sham condition during polysomnography.

What was found

Specific disruption of slow wave activity correlated with an increase in cerebrospinal fluid amyloid-β40 (r = 0.610, P = 0.009). This correlation was specific to slow wave activity and was not observed for total sleep duration or sleep efficiency, nor for total protein, tau, YKL-40, or hypocretin. In addition, worse home sleep efficiency over the six nights preceding lumbar puncture was associated with higher cerebrospinal fluid tau (r = 0.543, P = 0.045).

Why it matters

This study directly implicates slow wave sleep disruption as a specific physiological driver of acute central amyloid-β accumulation, linking non-REM sleep quality to early Alzheimer's disease biomarker dynamics.

Limits

The sample size was small (n = 17) and limited to healthy middle-aged adults. The abstract does not provide absolute biomarker values or confidence intervals, and the study measures acute fluid biomarkers rather than chronic plaque deposition or cognitive decline.

Cited by